title: Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial.
abstract: Mitochondrial dysfunction plays a major role in the pathogenesis of Parkinson disease (PD). Creatine (Cr) is an ergogenic compound that exerts neuroprotective effects in animal models of PD. We conducted a 2-year placebo-controlled randomized clinical trial on the effect of Cr in 60 patients with PD. Cr improved patient mood and led to a smaller dose increase of dopaminergic therapy but had no effect on overall Unified Parkinson's Disease Rating Scale scores or dopamine transporter SPECT.
authors.affiliation: Department of Neurology, Klinikum Grosshadern, Klinikum Grosshadern, University of Munich, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Bender
authors.forename: W
authors.initials: W
authors.lastname: Koch
authors.forename: M
authors.initials: M
authors.lastname: Elstner
authors.forename: Y
authors.initials: Y
authors.lastname: Schombacher
authors.forename: J
authors.initials: J
authors.lastname: Bender
authors.forename: M
authors.initials: M
authors.lastname: Moeschl
authors.forename: F
authors.initials: F
authors.lastname: Gekeler
authors.forename: B
authors.initials: B
authors.lastname: Müller-Myhsok
authors.forename: T
authors.initials: T
authors.lastname: Gasser
authors.forename: K
authors.initials: K
authors.lastname: Tatsch
authors.forename: T
authors.initials: T
authors.lastname: Klopstock
mesh_terms: D000284:Administration, Oral; D001921:Brain / Q000000981:diagnostic imaging* / Q000187:drug effects*; D003401:Creatine / Q000008:administration & dosage*; D019587:Dietary Supplements; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D010865:Pilot Projects; D015990:Placebo Effect; D011877:Radionuclide Imaging; D016896:Treatment Outcome
chemical_list: D003401:Creatine